Literature DB >> 18589307

Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model.

Tong-Hsien Chow1, Yi-Yu Lin, Jeng-Jong Hwang, Hsin-Ell Wang, Yun-Long Tseng, Victor Fei Pang, Shyh-Jen Wang, Jacqueline Whang-Peng, Gann Ting.   

Abstract

Colorectal carcinoma is a highly prevalent and common cause of cancer in Taiwan. There is still no available cure for this malignant disease. To address this issue, we applied the multimodality of molecular imaging to explore the efficacy of diagnostic and therapeutic nanoradiopharmaceuticals in an animal model of human colorectal adenocarcinoma [colorectal cancer (CRC)] that stably expresses luciferase (luc) as a reporter. In this study, an in vivo therapeutic efficacy evaluation of dual-nanoliposome (100 nm in diameter) encaged vinorelbine (VNB) and (111)In-oxine on HT-29/luc mouse xenografts was carried out. HT-29/luc tumor cells were transplanted subcutaneously into male SCID mice. Multimodality of molecular imaging approaches including bioluminescence imaging (BLI), gamma scintigraphy, whole-body autoradiography (WBAR) and in vivo tumor growth tracing, histopathology and biochemistry/hematology analyses were applied on xenografted SCID mice to study the treatments with 6% polyethylene glycol (PEG) of (111)In-NanoX/VNB-liposomes. In vivo tumor growth tracing and BLI showed that tumor volume could be completely inhibited by the combination therapy with (111)In-VNB-liposomes and by chemotherapy with NanoX/VNB-liposomes (i.e., without Indium-111) (P<.01). The nuclear medicine images of gamma scintigraphy and WBAR also revealed the conspicuous inhibition of tumor growth by the combination therapy with (111)In-VNB-liposomes. Animal body weights, histopathology and biochemistry/hematology analyses were used to confirm the safety and feasibility of radiopharmaceuticals. A synergistic therapeutic effect on CRC xenografted SCID mice was proven by combining an Auger electron-emitting radioisotope (Indium-111) with an anticancer drug (VNB). This study further demonstrates the beneficial potential applications of multimodality molecular imaging as part of the diagnostic and therapeutic approaches available for the evaluation of new drugs and other strategic approaches to disease treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589307     DOI: 10.1016/j.nucmedbio.2008.04.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  14 in total

1.  Mirtazapine inhibits tumor growth via immune response and serotonergic system.

Authors:  Chun-Kai Fang; Hong-Wen Chen; I-Tsang Chiang; Chia-Chieh Chen; Jyh-Fei Liao; Ton-Ping Su; Chieh-Yin Tung; Yosuke Uchitomi; Jeng-Jong Hwang
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

2.  Pharmacokinetics and dosimetry of (111)In/(188)Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.

Authors:  Yi-Yu Lin; Chih-Hsien Chang; Jia-Je Li; Michael G Stabin; Ya-Jen Chang; Liang-Cheng Chen; Ming-Hsien Lin; Yun-Long Tseng; Wuu-Jyh Lin; Te-Wei Lee; Gann Ting; Cheng Allen Chang; Fu-Du Chen; Hsin-Ell Wang
Journal:  Cancer Biother Radiopharm       Date:  2011-06-28       Impact factor: 3.099

3.  Improving chemoradiotherapy with nanoparticle therapeutics.

Authors:  Michael Joseph Eblan; Andrew Zhuang Wang
Journal:  Transl Cancer Res       Date:  2013-08-01       Impact factor: 1.241

Review 4.  Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy.

Authors:  Gann Ting; Chih-Hsien Chang; Hsin-Ell Wang; Te-Wei Lee
Journal:  J Biomed Biotechnol       Date:  2010-08-03

5.  Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus 111In Repeated Treatments in Human Colorectal Carcinoma With Multimodalities of Molecular Imaging.

Authors:  Yi-Chun Chien; Ying-Hsiang Chou; Wei-Hsun Wang; John Chun-Hao Chen; Wen-Shin Chang; Chia-Wen Tsai; DA-Tian Bau; Jeng-Jong Hwang
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069

6.  Therapeutic nanosystems for oncology nanomedicine.

Authors:  A S Gonçalves; A S Macedo; E B Souto
Journal:  Clin Transl Oncol       Date:  2012-07-27       Impact factor: 3.405

7.  Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound.

Authors:  Feng-Yi Yang; Hsin-Ell Wang; Ren-Shyan Liu; Ming-Che Teng; Jia-Je Li; Maggie Lu; Ming-Cheng Wei; Tai-Tong Wong
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats.

Authors:  Wen-Chuan Lee; Chih-Hsien Chang; Chih-Min Huang; Yu-Tse Wu; Liang-Cheng Chen; Chung-Li Ho; Tsui-Jung Chang; Te-Wei Lee; Tung-Hu Tsai
Journal:  Int J Nanomedicine       Date:  2012-02-09

9.  Tumor burden talks in cancer treatment with PEGylated liposomal drugs.

Authors:  Yi-Yu Lin; Hao-Wen Kao; Jia-Je Li; Jeng-Jong Hwang; Yun-Long Tseng; Wuu-Jyh Lin; Ming-Hsien Lin; Gann Ting; Hsin-Ell Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

Review 10.  Application of liposomes in drug development--focus on gastroenterological targets.

Authors:  Jian-Xin Zhang; Kun Wang; Zheng-Fa Mao; Xin Fan; De-Li Jiang; Min Chen; Lei Cui; Kang Sun; Sheng-Chun Dang
Journal:  Int J Nanomedicine       Date:  2013-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.